Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer, announced it will be presenting at several upcoming scientific congresses in May and June.
MILAN, Italy and NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced it will be presenting at several upcoming scientific congresses in May and June.
Details of the presentations are as follows:
American Society of Cell and Gene Therapy (ASGCT) 24th Annual Meeting, May 11-14, virtual
Title: Changes in the Tumor Microenvironment in Patients with Glioblastoma Multiforme Treated with IFN-a Immune Cell & Gene Therapy (TEM-GBM_001 Study)
Type: Oral presentation
Time: Friday May 14, 1.30-1.45 PM CET
2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, virtual
Title: A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study)
Type: Poster presentation
Day: June 4
European Hematology Association (EHA) 2021 Virtual Congress, June 9-17, virtual
Title: A Phase I-IIA Study of Genetically Modified TIE-2 Expressing Monocytes in Patients with Glioblastoma Multiforme (TEM-GBM Study)
Type: Oral presentation
Time: Sunday June 13, 7.45-8.30 PM CET
About Genenta Science
Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEMs). Temferon™, which is under investigation in a Phase I/IIa clinical trial in newly diagnosed Glioblastoma Multiforme patients, is not restricted to pre-selected tumor antigens nor type and has been designed to reach solid tumors, one of the main unresolved challenge in immuno-oncology. Based in Milan, Italy, and New York, USA, Genenta has raised more than €33.6 million (~$40 million) in three separate rounds of financing.
| Investor Relator - LifeSci Advisors: | Genenta Media/Investor Contact: | GENENTA SCIENCE Srl |
| Mary-Ann Chang, CFA | Stefania Mazzoleni, PhD | OSR - DiBit 1 - Via Olgettina, 58 - 20132 Milan (Italy) |
| +44 7483 28.48.53 | +39 339 709.59.31 | LaunchLabs - Alexandria Center, 14th Floor |
| mchang@lifesciadvisors.com | stefania.mazzoleni@genenta.com | 430 East 29th Street - New York, NY 10016 (USA) |
